Back to Search
Start Over
Ipilimumab with anti PD-1 (nivovlumab or pembrolizumab) after progression on first line anti-PD-1 therapy for advanced melanoma
- Source :
- Journal of Clinical Oncology. 36:e21552-e21552
- Publication Year :
- 2018
- Publisher :
- American Society of Clinical Oncology (ASCO), 2018.
-
Abstract
- e21552Background: Metastatic melanoma (MM) continues to present a challenge in clinical oncology. Anti-PD-1 antibodies (nivolumab, pembrolizumab) have improved outcomes for a significant number of ...
- Subjects :
- 0301 basic medicine
Clinical Oncology
Oncology
Cancer Research
medicine.medical_specialty
Metastatic melanoma
business.industry
First line
Anti pd 1
Ipilimumab
Pembrolizumab
03 medical and health sciences
030104 developmental biology
0302 clinical medicine
030220 oncology & carcinogenesis
Internal medicine
medicine
Nivolumab
business
medicine.drug
Advanced melanoma
Subjects
Details
- ISSN :
- 15277755 and 0732183X
- Volume :
- 36
- Database :
- OpenAIRE
- Journal :
- Journal of Clinical Oncology
- Accession number :
- edsair.doi...........9660b8e0e5421ef20c2e2b2a4823305c
- Full Text :
- https://doi.org/10.1200/jco.2018.36.15_suppl.e21552